World & BusinessBharat Biotech reportedly weighs an IPO to fund new therapies and potential acquisitions
The Economic Times reports that founder Krishna Ella says Bharat Biotech is expanding into cell and gene therapy and monoclonal antibodies after a two-year post-Covid reset.
TLDR
The Economic Times reports that Bharat Biotech is advancing programmes for TB, Nipah, Ebola and other diseases while exploring an IPO to fund new therapies and potential acquisitions. Founder Krishna Ella describes the company as “back in action” after a two-year post-Covid reset, with expansion beyond vaccines into cell and gene therapy and monoclonal antibodies. Ella says the company has around Rs 2,000 crore in revenue and is debt-free.